[go: up one dir, main page]

MX2011010311A - Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. - Google Patents

Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.

Info

Publication number
MX2011010311A
MX2011010311A MX2011010311A MX2011010311A MX2011010311A MX 2011010311 A MX2011010311 A MX 2011010311A MX 2011010311 A MX2011010311 A MX 2011010311A MX 2011010311 A MX2011010311 A MX 2011010311A MX 2011010311 A MX2011010311 A MX 2011010311A
Authority
MX
Mexico
Prior art keywords
making
methods
same
pharmaceutical formulations
derivatives
Prior art date
Application number
MX2011010311A
Other languages
English (en)
Other versions
MX361618B (es
Inventor
Teofilo Cardoso De Vasconcelos
Ricardo Jorge Dos Santos Lima
Pedro Miguel Da Costa Barrocas
Ligia Sofia De Castro Pereira
Rui Cerdeira De Campos Costa
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011010311(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of MX2011010311A publication Critical patent/MX2011010311A/es
Publication of MX361618B publication Critical patent/MX361618B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a composiciones y formulaciones farmacéuticas que comprenden por lo menos un ingrediente farmacéutico activo seleccionado de derivados de nitrocatecol de la fórmula I como se definen en este documento y sales, ésteres, hidratos, solvatos y otros derivados de los mismos y métodos para hacer las mismas.
MX2011010311A 2009-04-01 2010-03-31 Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas. MX361618B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16579409P 2009-04-01 2009-04-01
PCT/PT2010/000015 WO2010114405A2 (en) 2009-04-01 2010-03-31 Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same

Publications (2)

Publication Number Publication Date
MX2011010311A true MX2011010311A (es) 2012-03-07
MX361618B MX361618B (es) 2018-12-13

Family

ID=42229943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010311A MX361618B (es) 2009-04-01 2010-03-31 Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.

Country Status (15)

Country Link
US (3) US20100256194A1 (es)
EP (1) EP2413913B1 (es)
JP (2) JP5864410B2 (es)
KR (1) KR101824257B1 (es)
CN (2) CN102438595B (es)
AU (1) AU2010231962B2 (es)
BR (1) BRPI1016132B8 (es)
CA (1) CA2757418C (es)
DK (1) DK2413913T3 (es)
ES (1) ES2915698T3 (es)
MX (1) MX361618B (es)
PL (1) PL2413913T3 (es)
PT (1) PT2413913T (es)
RU (1) RU2550133C2 (es)
WO (1) WO2010114405A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2545178T3 (es) 2005-07-26 2015-09-09 Bial-Portela & Ca, S.A. Derivados de nitrocatecol como inhibidores de la COMT
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
CL2009000628A1 (es) 2008-03-17 2010-04-09 Bial Portela & Companhia S A Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros.
KR20210009441A (ko) 2009-04-01 2021-01-26 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2791134B1 (en) 2011-12-13 2019-09-25 BIAL - Portela & Cª S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
NO2699580T3 (es) 2014-01-24 2018-02-24
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
EP3728241A4 (en) * 2017-12-18 2021-02-24 Unichem Laboratories Ltd OPICAPONE PREPARATION PROCESS AND INTERMEDIARIES THEREOF
CN112055593B (zh) 2018-03-01 2024-04-09 阿斯利康(瑞典)有限公司 药物组合物
EP3823627A4 (en) 2018-07-17 2022-04-20 Insmed Incorporated CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY
CA3112994A1 (en) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
EP3860603A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
JP2023517690A (ja) 2020-03-13 2023-04-26 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 微粉化オピカポン
GB202011709D0 (en) 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
GB202016425D0 (en) 2020-10-16 2020-12-02 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
KR20230118933A (ko) 2020-12-17 2023-08-14 바이알 - 포르텔라 앤드 씨에이 에스에이 초기 특발성 파킨슨병에 대한 치료 요법
WO2022180649A1 (en) * 2021-02-26 2022-09-01 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
GB202212082D0 (en) 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
AU2024206233A1 (en) 2023-01-06 2025-08-21 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2024242579A1 (en) 2023-05-25 2024-11-28 Bial-Portela & Ca., S.A. Treatment regimens for early idiopathic parkinson's disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) * 1921-07-25 1925-04-07 Louis A Godbold Lubricator
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US4085563A (en) * 1977-01-31 1978-04-25 Campbell Soup Company Cookie dispensing apparatus
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4368668A (en) * 1981-05-15 1983-01-18 Veb Kombinat Polygraph "Werner Lamberz" Leipzig Printing plate mounting arrangement
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US6206110B1 (en) * 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
WO2000017175A1 (en) * 1998-09-18 2000-03-30 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
GB2344819A (en) * 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1356046B1 (en) * 2000-11-28 2009-10-14 ZymoGenetics, L.L.C. Cytokine receptor zcytor19
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
EP1356816B1 (en) * 2001-01-29 2009-12-23 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
US7041685B2 (en) * 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
CN100364531C (zh) * 2002-12-18 2008-01-30 西托维亚公司 3,5－二取代－[1,2,4]－二唑及类似物和其用途
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
EP1673071A1 (en) * 2003-09-29 2006-06-28 Novo Nordisk Femcare AG Improved stability of progestogen formulations
US7300406B2 (en) * 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP2007535551A (ja) * 2004-04-28 2007-12-06 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20080051441A1 (en) * 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
WO2006132914A2 (en) * 2005-06-03 2006-12-14 Abbott Laboratories Cyclobutyl amine derivatives
JP2007024970A (ja) * 2005-07-12 2007-02-01 Miyakawa:Kk 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置
ES2545178T3 (es) * 2005-07-26 2015-09-09 Bial-Portela & Ca, S.A. Derivados de nitrocatecol como inhibidores de la COMT
US20070048384A1 (en) * 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
JP2008162955A (ja) * 2006-12-28 2008-07-17 Chugai Pharmaceut Co Ltd バリン含有高密度顆粒剤
DK2481410T3 (en) * 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
PE20081891A1 (es) * 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
CL2009000628A1 (es) * 2008-03-17 2010-04-09 Bial Portela & Companhia S A Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros.

Also Published As

Publication number Publication date
BRPI1016132B1 (pt) 2020-11-24
BRPI1016132B8 (pt) 2021-05-25
AU2010231962A1 (en) 2011-11-17
KR101824257B1 (ko) 2018-01-31
WO2010114405A2 (en) 2010-10-07
PT2413913T (pt) 2022-06-09
US20100256194A1 (en) 2010-10-07
RU2011143619A (ru) 2013-05-10
DK2413913T3 (da) 2022-06-13
JP5864410B2 (ja) 2016-02-17
CN102438595A (zh) 2012-05-02
ES2915698T3 (es) 2022-06-24
EP2413913B1 (en) 2022-05-18
US20210315824A1 (en) 2021-10-14
KR20120008040A (ko) 2012-01-25
JP2012522764A (ja) 2012-09-27
AU2010231962B2 (en) 2015-05-21
BRPI1016132A2 (pt) 2016-04-19
CA2757418A1 (en) 2010-10-07
JP2016020369A (ja) 2016-02-04
CN102438595B (zh) 2016-04-27
US20190008774A1 (en) 2019-01-10
EP2413913A2 (en) 2012-02-08
CN105816456A (zh) 2016-08-03
RU2550133C2 (ru) 2015-05-10
JP6336420B2 (ja) 2018-06-06
PL2413913T3 (pl) 2022-09-26
MX361618B (es) 2018-12-13
CA2757418C (en) 2021-06-15
WO2010114405A3 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
MX361618B (es) Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MY183312A (en) Pharmaceutical formulation
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
GEAP202213376A (en) Inhibitors of influenza viruses replication
IN2014MN02598A (es)
IN2014CN04530A (es)
MX2012000414A (es) Derivados piridin-4-ilo.
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
WO2012030685A3 (en) Indazole derivatives useful as erk inhibitors
EP3626253A3 (en) Stable formulations of linaclotide
PH12013501704A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
AU2010246749A8 (en) Thiophene derivatives
MX2011012523A (es) Esteres cetalicos de anhidropentitoles y usos de los mismos.
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
BR112012011328A2 (pt) inibidores de akt
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
EA201270302A1 (ru) Безводные формы производных пиридина
TN2012000105A1 (en) Spirolactam derivatives and uses of same
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Legal Events

Date Code Title Description
FG Grant or registration